Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Arthur S. Waldbaum"'
Autor:
Jane R. Schwebke, Belvia A. Carter, Arthur S. Waldbaum, Kathy J. Agnew, Jeremy R.A. Paull, Clare F. Price, Alex Castellarnau, Philip McCloud, George R. Kinghorn
Publikováno v:
European Journal of Obstetrics & Gynecology and Reproductive Biology: X, Vol 10, Iss , Pp 100121- (2021)
Objective: The objective of the study was to confirm the efficacy and safety of Astodrimer 1% Gel to prevent recurrence of bacterial vaginosis. Study design: 864 women with a diagnosis of bacterial vaginosis and a history of recurrent bacterial vagin
Externí odkaz:
https://doaj.org/article/4bd950dfda1d4fae93a9542dee9df836
Autor:
Arthur S. Waldbaum, Kathy Agnew, Belvia A. Carter, Philip McCloud, Jane R. Schwebke, George R. Kinghorn, Alex Castellarnau, Clare F. Price, Jeremy R.A. Paull
Publikováno v:
European Journal of Obstetrics & Gynecology and Reproductive Biology: X, Vol 10, Iss, Pp 100121-(2021)
European Journal of Obstetrics & Gynecology and Reproductive Biology: X
European Journal of Obstetrics & Gynecology and Reproductive Biology: X
Highlights • Recurrent bacterial vaginosis impacts on women and carries a high financial burden. • Astodrimer 1% Gel was superior to placebo for prevention of recurrent BV. • Astodrimer 1% Gel was well tolerated when used every second day for 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f78fbeecf12994b8cd9b90f1c36fa7d
https://doi.org/10.1101/2020.08.06.20159475
https://doi.org/10.1101/2020.08.06.20159475
Autor:
Arthur S. Waldbaum, Philip McCloud, Stephanie R. Edmondson, Jeremy R.A. Paull, Alex Castellarnau, Jane R. Schwebke, George R. Kinghorn, Clare F. Price
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 5, p e0232394 (2020)
PLoS ONE, Vol 15, Iss 5, p e0232394 (2020)
BackgroundAstodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis.Methods132 women with bacterial vaginosis were randomize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e586080984c6fa315e032b3cfd4e3c
http://europepmc.org/articles/PMC7197797
http://europepmc.org/articles/PMC7197797
Autor:
Belvia A. Carter, Gilbert G. G. Donders, Steven E. Chavoustie, Klaus Peters, Jane R. Schwebke, George R. Kinghorn, Arthur S. Waldbaum, Clare F. Price, Jeremy R.A. Paull, Philip McCloud, Alex Castellarnau
Publikováno v:
European journal of obstetrics and gynecology and reproductive biology
Objective: Astodrimer is a dendrimer formulated in a vaginal gel to treat bacterial vaginosis (BV) and prevent recurrence. The objective of these studies was to confirm the efficacy and safety of Astodrimer 1 % Gel for treatment of BV. Study Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed582be307cb3dc38702455ba3d41959
https://pubmed.ncbi.nlm.nih.gov/31812702
https://pubmed.ncbi.nlm.nih.gov/31812702
Autor:
Paul Nyirjesy, Howard A. Reisman, Arthur S. Waldbaum, Mark Jacobs, Steven E. Chavoustie, Sharon L. Hillier, Sharon F. Levy
Publikováno v:
Journal of Lower Genital Tract Disease
Metronidazole vaginal gel 1.3% once daily for 1, 3, or 5 days provides similar efficacy, safety, and tolerability as metronidazole vaginal gel 0.75% once daily for 5 days.
Objective Metronidazole vaginal gel (MVG) 0.75% is a US Food and Drug Adm
Objective Metronidazole vaginal gel (MVG) 0.75% is a US Food and Drug Adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8185f31c4395ac9d32b54a0cb2b65ec0
https://doi.org/10.1097/lgt.0000000000000062
https://doi.org/10.1097/lgt.0000000000000062
Autor:
Nikki Adetoro, Paul Nyirjesy, Carol J. Braun, Franklin G. Morgan, Arthur S. Waldbaum, Sharon L. Hillier, Jane R. Schwebke
Publikováno v:
Obstetrics and gynecology. 130(2)
To evaluate secnidazole as a single oral dose treatment for bacterial vaginosis in a phase 2 randomized, double-blind, placebo-controlled study.In a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study, women with bacterial vagin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faea4581151893ee5dc6cbdddedbd544
https://pubmed.ncbi.nlm.nih.gov/28697102
https://pubmed.ncbi.nlm.nih.gov/28697102
Autor:
Fernand, Labrie, David F, Archer, Céline, Bouchard, Ginette, Girard, Normand, Ayotte, John C, Gallagher, Leonello, Cusan, Mira, Baron, François, Blouin, Arthur S, Waldbaum, William, Koltun, David J, Portman, Isabelle, Côté, Lyne, Lavoie, Adam, Beauregard, Claude, Labrie, Céline, Martel, John, Balser, Érick, Moyneur, Douglas, Young
Publikováno v:
Maturitas. 81(1)
An objective was to analyze the time course of efficacy of daily intravaginal administration of 0.5% (6.5mg) DHEA (prasterone) for 52 weeks on the moderate to severe (MS) symptoms and signs of vulvovaginal atrophy (VVA).Five hundred twenty-one postme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deeec1ef50722920960d88f6184dbf1a
https://pubmed.ncbi.nlm.nih.gov/25771041
https://pubmed.ncbi.nlm.nih.gov/25771041
Publikováno v:
Fertility and Sterility. 78:S25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cbac7e86d0b6c208418dff322704bcd
https://doi.org/10.1016/s0015-0282(02)03445-3
https://doi.org/10.1016/s0015-0282(02)03445-3